Metabolix (MBLX)
Metabolix R&D Expense: 6.045M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MBLX R&D Expense Rankings
| Overall | 42nd percentile | 1014 of 1763 |
| Sector | 38th percentile | 131 of 214 in Basic Materials |
| Industry | 51st percentile | 14 of 29 in Specialty Chemicals |
MBLX R&D Expense Range, Past 5 Years
| Minimum | 5.026M | Jun 2007 |
| Maximum | 6.571M | Sep 2008 |
| Average | 5.970M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these MBLX related companies
MBLX News
Metabolix to Webcast Its Presentation at 10th Annual Ardour Capital Energy Technology Conference
May 29, 9:00AM Business Wire
May 29, 9:00AM Business Wire
$MBLX http://stks.co/3zlQ Rumors of Metabolix presenting new direction after being unloaded by $ADM. Alert @ 2.5
about 5 days ago by abdulalikon
about 5 days ago by abdulalikon
$MBLX Insider Buy: $220K of stock bought by Matthew Strobeck on May 11, 2012 http://stks.co/3ooZ
about 16 days ago by MarketBrief
about 16 days ago by MarketBrief
$MBLX I dont see this stock coming back right away. 1.75 might be bottom till the come back. Next week should be a good indicator.
about 20 days ago by stkwatcherpro
about 20 days ago by stkwatcherpro
$MBLX coming off 52 wk low and ready to head back to 8 looks a great buy in mid 2's
about 22 days ago by epime7heus
about 22 days ago by epime7heus
was hoping $MBLX to reach 4, and nice if $YRCW broke 10, next resistance 85, speculative.
about 33 days ago by meatloose
about 33 days ago by meatloose
Metabolix Reports First Quarter 2012 Financial Results and Provides Business Update
Apr 26, 4:01PM Business Wire
Apr 26, 4:01PM Business Wire
$SHLD on the mends? got more $MBLX for earnings, could be something, could be nothing.
about 35 days ago by meatloose
about 35 days ago by meatloose
Ball Horticultural and Costa Farms Launch New Mirel-based SoilWrap Biodegradable Plant Container
Apr 23, 9:00AM Business Wire
Apr 23, 9:00AM Business Wire
Ball Horticultural and Floral Plant Growers Launch New Mirel-based SoilWrap Biodegradable Plant Container
Apr 23, 9:00AM Business Wire
Apr 23, 9:00AM Business Wire
Metabolix to Conduct a Webcast of Its First Quarter Fiscal Year 2012 Earnings Call
Apr 10, 9:00AM Business Wire
Apr 10, 9:00AM Business Wire
Hagens Berman Continues Metabolix Investigation: 13 Days Remain Before Lead Plaintiff Deadline
Apr 04, 8:33PM PR Newswire
Apr 04, 8:33PM PR Newswire
$MBLX forms bearish "Continuation Wedge" chart pattern. http://stks.co/37vj
about 62 days ago by RecogniaEvents
about 62 days ago by RecogniaEvents
Block & Leviton LLP Files Securities Class Action Against Metabolix, Inc. and Certain of its Officers
Mar 27, 4:38PM PR Newswire
Mar 27, 4:38PM PR Newswire
$MBLX--Director purchased 100k shares at $3.12. Stock closed at $3.18, do your own research. Huge short position.
about 77 days ago by MicroInsider
about 77 days ago by MicroInsider
Metabolix Grants a Patent License to NatureWorks LLC for New Biopolymer Blends
Mar 14, 9:02AM Benzinga
Mar 14, 9:02AM Benzinga
36 Days Remain Before Lead Plaintiff Deadline in Metabolix Case, Hagens Berman Reminds Investors
Mar 12, 3:00PM PR Newswire
Mar 12, 3:00PM PR Newswire
$MBLX http://stks.co/2mFu Long setup. Gap-fill play. Watch the $3.11 level.
about 80 days ago by VexTrades
about 80 days ago by VexTrades
Listen to $MBLX Q4 2011 earnings call - live at 05:00 PM, ondemand after - http://stks.co/2hO4
about 85 days ago by earningscast
about 85 days ago by earningscast
Metabolix Reports Fourth Quarter and Full Year 2011 Financial Results and Provides Business Update
Mar 06, 4:01PM Business Wire
Mar 06, 4:01PM Business Wire
Glancy Binkow & Goldberg LLP Announces Investigation of Metabolix, Inc.
Mar 01, 6:30PM Business Wire
Mar 01, 6:30PM Business Wire
@jimcramer I got into $MBLX at 2.64 what do you think about it as we come up on earnings. Possibility of another JV after the $ADM breakup.
about 91 days ago by Fakemoney123
about 91 days ago by Fakemoney123
$MBLX http://stks.co/2bZV Hot setup; Low risk with stop @ 20 DMA; Additional notes on chart
about 91 days ago by amitp_gupta
about 91 days ago by amitp_gupta
Robbins Umeda LLP Announces the Filing of a Class Action Lawsuit Against Metabolix, Inc.
Feb 28, 6:08PM Business Wire
Feb 28, 6:08PM Business Wire
Law Offices of Howard G. Smith Announces Investigation of Metabolix, Inc.
Feb 24, 9:30PM Business Wire
Feb 24, 9:30PM Business Wire
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Metabolix, Inc.
Feb 24, 7:04PM Business Wire
Feb 24, 7:04PM Business Wire
Metabolix to Conduct a Webcast of Its Fourth Quarter and Fiscal Year 2011 Earnings Call
Feb 21, 9:00AM Business Wire
Feb 21, 9:00AM Business Wire
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Metabolix, Inc.
Feb 20, 8:23PM Business Wire
Feb 20, 8:23PM Business Wire
$MBLX Keeps finding support at the T-Line after the T-Line cross on 2/06 http://stks.co/2KaF
about 111 days ago by GoofyGolfa
about 111 days ago by GoofyGolfa
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MBLX | 1.95 | -0.03 | -1.52% | 67.60M |
| LXK | 25.35 | -0.76 | -2.91% | 1.858B |
| LWAY | 10.06 | +0.10 | +1.00% | 165.29M |
| LVS | 47.42 | -1.61 | -3.28% | 35.99B |
| LVLT | 21.60 | -0.74 | -3.31% | 4.828B |
| LVL | 12.16 | -0.18 | -1.46% | |
| LVB | 22.35 | -0.09 | -0.40% | 277.36M |
| LUX | 32.28 | -1.45 | -4.30% | 15.76B |
| LUV | 8.83 | -0.11 | -1.23% | 6.910B |
| LINE | 35.56 | -0.51 | -1.41% | 7.191B |
